Tom Li

Image
Tom Li

Tom Li, PhD

Title
Associate Professor
Unit / Department / Division
Medicinal Chemistry and Pharmacognosy
Address
336 Parks Hall
Email Address
Phone Number

Professional Interests

Professional Interests

The research area of Dr. Li focuses in the design, synthesis and biochemical testing of steroidal and non-steroidal steroid sulfatase inhibitors as potential agents for the treatment of hormone-dependent cancers. Estrogen levels in breast tumors of post-menopausal women are as much as 10 times higher than estrogen levels in plasma, presumably due to in situ formation of estrogen. The major source of estrogen in breast cancer cells may be conversion of estrone sulfate to estrone by the enzyme estrone sulfatase. One of their goals is to develop potent estrone sulfatase inhibitors as potential agents for the treatment of estrogen-dependent breast cancer. They have synthesized both the steroidal and non-steroidal estrone sulfatase inhibitors.

Education

  • 1988, PhD, The Ohio State University, Medicinal Chemistry
  • 1983, BS, University of Wyoming, Pharmacy
  • 1980, Please enter degree name, University of Nevada, Pre-Pharmacy

Honors

  • President's Award for Excellence, 1997
  • School of Pharmacy Award for Excellence in Scholarship, 1997
  • Distinguished Presentation of the 14th annual meeting, Graduate Student Forum, 1988
  • University Graduate Associate Teaching Award, 1987
  • University Fellowship, 1983 - 1984

Journal Articles

  • Wang B, Li PK, Ma JX, Chen D. Therapeutic Effects of a Novel Phenylphthalimide Analog for Corneal Neovascularization and Retinal Vascular Leakage. Invest Ophthalmol Vis Sci. 2018 Jul 02;59(8):3630-3642.
  • Arend RC, Londoño-Joshi AI, Gangrade A, Katre AA, Kurpad C, Li Y, Samant RS, Li PK, Landen CN, Yang ES, Hidalgo B, Alvarez RD, Straughn JM, Forero A, Buchsbaum DJ. Correction: Niclosamide and its analogs are potent inhibitors of Wnt/β-catenin, mTOR and STAT3 signaling in ovarian cancer. Oncotarget. 2018 Apr 10;9(27):19459.
  • Tang Z, Acuña UM, Fernandes NF, Chettiar S, Li PK, DE Blanco EC. Structure-Activity Relationship of Niclosamide Derivatives. Anticancer Res. 2017 06;37(6):2839-2843.
  • Sugimoto Y, Sawant DB, Fisk HA, Mao L, Li C, Chettiar S, Li PK, Darby MV, Brueggemeier RW. Novel pyrrolopyrimidines as Mps1/TTK kinase inhibitors for breast cancer. Bioorg Med Chem. 2017 04 01;25(7):2156-2166.
  • Lin L, Jou D, Wang Y, Ma H, Liu T, Fuchs J, Li PK, Lü J, Li C, Lin J. STAT3 as a potential therapeutic target in ALDH+ and CD44+/CD24+ stem cell-like pancreatic cancer cells. Int J Oncol. 2016 Dec;49(6):2265-2274.
  • Arend RC, Londoño-Joshi AI, Gangrade A, Katre AA, Kurpad C, Li Y, Samant RS, Li PK, Landen CN, Yang ES, Hidalgo B, Alvarez RD, Straughn JM, Forero A, Buchsbaum DJ. Niclosamide and its analogs are potent inhibitors of Wnt/β-catenin, mTOR and STAT3 signaling in ovarian cancer. Oncotarget. 2016 Dec 27;7(52):86803-86815.
  • Zhao J, Yu H, Liu Y, Gibson SA, Yan Z, Xu X, Gaggar A, Li PK, Li C, Wei S, Benveniste EN, Qin H. Protective effect of suppressing STAT3 activity in LPS-induced acute lung injury. Am J Physiol Lung Cell Mol Physiol. 2016 11 01;311(5):L868-L880.
  • Walters Haygood CL, Arend RC, Gangrade A, Chettiar S, Regan N, Hassmann CJ, Li PK, Hidalgo B, Straughn JM, Buchsbaum DJ. Niclosamide Analogs for Treatment of Ovarian Cancer. Int J Gynecol Cancer. 2015 Oct;25(8):1377-85.
  • Li Y, Li PK, Roberts MJ, Arend RC, Samant RS, Buchsbaum DJ. Multi-targeted therapy of cancer by niclosamide: A new application for an old drug. Cancer Lett. 2014 Jul 10;349(1):8-14.
  • Kim TD, Fuchs JR, Schwartz E, Abdelhamid D, Etter J, Berry WL, Li C, Ihnat MA, Li PK, Janknecht R. Pro-growth role of the JMJD2C histone demethylase in HCT-116 colon cancer cells and identification of curcuminoids as JMJD2 inhibitors. Am J Transl Res. 2014;6(3):236-47.